Related Experiment Video
Updated: Sep 16, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Preferences of Patients With cTTP and Other Chronic Conditions for At-Home Prophylactic Infusions: A Discrete Choice
Laurie Batchelder1, Montserrat Casamayor2, Ana María Rodríguez3
1Patient Centred Solutions, IQVIA, Reading, UK.
None:
Gaining an understanding of patient preferences regarding treatment administration can help inform approaches to patient care. A discrete choice experiment survey comprising of 7 attributes (treatment environment, convenience, travel times, waiting times, interactions with patients, interactions with healthcare providers, and concerns about complications) was used to assess the stated preferences of patients with chronic conditions, including congenital thrombotic thrombocytopenic purpura (cTTP), for receiving intravenous prophylactic infusions administered at home versus in an outpatient setting. The survey also contained a time trade-off exercise. In total, 307 survey responses were included in the analyses, of which 25 were from patients with cTTP. An overall preference for receiving infusions at home was reported by 137 patients (44.6%), and a high proportion of patients (n = 187, 60.9%) were willing to trade at least 12 months of their lives to receive treatment at home. Patients considered being comfortable with the treatment environment to be the most important attribute. These findings provide insights into the importance of the treatment setting preferences of patients with chronic conditions receiving prophylactic infusions.
More Related Videos
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
10:32Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...